Arkansas Pathology Laboratory and Its Owners Pay $30M to Settle Allegations of Kickbacks and Unnecessary Medical Testing

Advanced Pathology Solutions PLLC (formerly known as Advanced Pathology Solutions LLC), an anatomic pathology laboratory headquartered in North Little Rock, Arkansas, and its management services organization, APS MSO LLC (together, “APS”), along with current and former owners Kevin Hannah, Donell Burkett, and Daniel Hunter Pledger have agreed to pay a total of $30 million to the United States to resolve allegations that APS and its owners furnished unlawful kickbacks and ordered medically unnecessary pathology testing services. “Healthcare referrals must be based on the best decision for patients, not the influence of kickbacks,” said Assistant Attorney General Brett A. Shumate of the Justice Department’s Civil Division. “This settlement demonstrates the Department’s commitment to hold accountable both corporations and individuals who profit from improper kickback arrangements and who burden federal healthcare programs with claims for medically unnecessary services.” The settlement resolves allegations made by the United States in a complaint filed on April 8, in the U.S. District Court for the Eastern District of Arkansas. In its complaint, the United States alleged that, from 2015 through July 2022, APS and its owners violated the False Claims Act (FCA) by providing unlawful kickbacks to gastroenterology practices to induce the referral of pathology testing to APS resulting in false claims to federal healthcare programs. The government’s complaint focused on a business model developed by APS and its owners, in which APS set up and managed limited-purpose laboratories (known as “lean labs”) in gastroenterology practices nationwide that enabled the practices to bill for preparing and staining biopsy specimen slides. The complaint alleged that in exchange for various benefits furnished by APS, the gastroenterology practices agreed to exclusively refer their patients to APS by shipping their patients’ slides to APS’s lab in North Little Rock for pathologist interpretation and review. The United States alleged that the arrangements between APS and the gastroenterology practices were improper financial relationships through which APS provided kickbacks to induce the practices to steer their patients to APS. The United States further alleged that APS and its owners submitted and caused the submission of claims to federal healthcare programs for unnecessary testing. Specifically, APS directed lean lab personnel to automatically order certain special tests (called “special stains”) before a pathologist reviewed a routine test (a hematoxylin and eosin stain) to determine whether additional testing was necessary. By following the special stain protocol, APS and the lean labs ordered special stains that were not medically reasonable and necessary and were ineligible for Medicare coverage or reimbursement. In many cases, APS would also order additional “confirmatory” immunohistochemical testing on patient samples it received from the lean labs, which was also not medically necessary. In addition to resolving the allegations in the United States’ complaint, the settlement announced today also resolves allegations that from Nov. 1, 2018, to Nov. 30, 2020, APS and CEO Kevin Hannah knowingly and willfully provided unlawful kickbacks to an individual named Richard Sorgnard in the form of volume-based commission payments to induce the referral of patients to APS for epidermal nerve fiber density (“ENFD”) testing. Sorgnard, who previously entered into a settlement with the government to resolve related claims, encouraged medical providers and practices to order ENFD testing from APS for their patients, and in exchange, APS paid Sorgnard 4% of all payments APS collected for ENFD testing referred. The United States contends that this arrangement violated the Anti-Kickback Statute and resulted in false claims under the FCA. In connection with the settlement, APS entered into a five-year Corporate Integrity Agreement (CIA) with the U.S. Department of Health and Human Services Office of Inspector General. The CIA requires APS to implement numerous auditing and accountability provisions, including implementation of a robust compliance program, new training and education requirements, and a review of physician referral relationships. The complaint follows three lawsuits that were originally filed under the qui tam or whistleblower provisions of the FCA. Under the FCA, private parties can file an action on behalf of the United States and receive a portion of the recovery. The FCA permits the United States to intervene in and take over the action, as it has done here. If a defendant is found liable for violating the FCA, the United States may recover three times the amount of its losses plus applicable penalties.